Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Neurology Israel

Alcobra names new board member

This article was originally published in Scrip

Executive Summary

Tel Aviv, Israel-based Alcobra, an emerging pharmaceutical company focused on the development of new medications for cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, has appointed Dr Joao Siffert to its board of directors. Dr Siffert is currently executive vice-president of R&D and chief medical officer of Avanir Pharmaceuticals (a subsidiary of Otsuka Pharmaceutical).

Table

View full table

Topics

Related Companies

Tags:
Neurology Israel
Latest Headlines

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs

Amgen Planning Pivotal Obesity Program For MariTide

See All
UsernamePublicRestriction

Register

SC029272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By